458 related articles for article (PubMed ID: 23302469)
1. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients.
Qiu S; Lin S; Hu D; Feng Y; Tan Y; Peng Y
J Transl Med; 2013 Jan; 11():10. PubMed ID: 23302469
[TBL] [Abstract][Full Text] [Related]
2. miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
Chen H; Li X; Li W; Zheng H
J Transl Med; 2015 Feb; 13():69. PubMed ID: 25890369
[TBL] [Abstract][Full Text] [Related]
3. Microrna-1224-5p Is a Potential Prognostic and Therapeutic Biomarker in Glioblastoma: Integrating Bioinformatics and Clinical Analyses.
Wei X; Zhang QM; Liu C; Wu S; Nong WX; Ge YY; Lin LN; Li F; Xie XX; Luo B
Curr Med Sci; 2022 Jun; 42(3):584-596. PubMed ID: 35678909
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible miR-196a modulates glioblastoma cell proliferation and migration through complex regulation of NRAS.
Takkar S; Sharma V; Ghosh S; Suri A; Sarkar C; Kulshreshtha R
Cell Oncol (Dordr); 2021 Apr; 44(2):433-451. PubMed ID: 33469841
[TBL] [Abstract][Full Text] [Related]
5. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
[TBL] [Abstract][Full Text] [Related]
6. Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.
Yerukala Sathipati S; Huang HL; Ho SY
BMC Genomics; 2016 Dec; 17(Suppl 13):1022. PubMed ID: 28155650
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Glioblastoma Patients' Plasma Revealed the Presence of MicroRNAs with a Prognostic Impact on Survival and Those of Viral Origin.
Herman A; Gruden K; Blejec A; Podpečan V; Motaln H; Rožman P; Hren M; Zupančič K; Veber M; Verbovšek U; Lah Turnšek T; Porčnik A; Koršič M; Knežević M; Jeras M
PLoS One; 2015; 10(5):e0125791. PubMed ID: 25950799
[TBL] [Abstract][Full Text] [Related]
8. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics analysis of miRNA expression profile between primary and recurrent glioblastoma.
Bo LJ; Wei B; Li ZH; Wang ZF; Gao Z; Miao Z
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3579-86. PubMed ID: 26502847
[TBL] [Abstract][Full Text] [Related]
10. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
[TBL] [Abstract][Full Text] [Related]
11. MiR-330-3p and miR-485-5p as biomarkers for glioblastoma: An integrated bioinformatics and experimental study.
Rahmati Y; Alivand M; Mollanoori H
Comput Biol Chem; 2021 Jun; 92():107458. PubMed ID: 33761401
[TBL] [Abstract][Full Text] [Related]
12. Propolis Extract Regulates microRNA Expression in Glioblastoma and Brain Cancer Stem Cells.
C Yilmaz U; Bagca BG; Karaca E; Durmaz A; Durmaz B; Aykut A; Kayalar H; Avci CB; Susluer SY; Pariltay E; Gunduz C; Cogulu O
Anticancer Agents Med Chem; 2022; 22(2):378-389. PubMed ID: 33949939
[TBL] [Abstract][Full Text] [Related]
13. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme.
Qiu S; Huang D; Yin D; Li F; Li X; Kung HF; Peng Y
Biochim Biophys Acta; 2013 Oct; 1832(10):1697-707. PubMed ID: 23707559
[TBL] [Abstract][Full Text] [Related]
14. A 4-miRNA signature to predict survival in glioblastomas.
Hermansen SK; Sørensen MD; Hansen A; Knudsen S; Alvarado AG; Lathia JD; Kristensen BW
PLoS One; 2017; 12(11):e0188090. PubMed ID: 29136645
[TBL] [Abstract][Full Text] [Related]
15. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
16. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
17. The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression.
Wu W; Yu T; Wu Y; Tian W; Zhang J; Wang Y
J Exp Clin Cancer Res; 2019 Mar; 38(1):133. PubMed ID: 30898167
[TBL] [Abstract][Full Text] [Related]
18. Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma.
Chen J; Yang L; Wang X
Cancer Biomark; 2017 Dec; 20(4):521-526. PubMed ID: 28946553
[TBL] [Abstract][Full Text] [Related]
19. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.
Niyazi M; Pitea A; Mittelbronn M; Steinbach J; Sticht C; Zehentmayr F; Piehlmaier D; Zitzelsberger H; Ganswindt U; Rödel C; Lauber K; Belka C; Unger K
Oncotarget; 2016 Jul; 7(29):45764-45775. PubMed ID: 27302927
[TBL] [Abstract][Full Text] [Related]
20. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
